Articles by Walter Armstrong

Forecast 2009: Up in the Air

Jan 1, 2009
By: Walter Armstrong

We know what you're thinking: new president, rotten economy, patent cliff. Do you feel Evel? Well, do you?

The New Deals

Dec 1, 2008
By: Walter Armstrong

Everything you wanted to know about the year's most important deals—and what to watch for in the future

The Japanese Pharma League has spent almost $50 billion in a whirlwind year of foreign deals. But as the case of Astellas illustrates, becoming a global player in a game of catch-up will cost more than just money
Oct 1, 2008
By: Walter Armstrong

Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?

The Drug Vote '08

A head-to-head analysis of the two brands
Oct 1, 2008
By: Walter Armstrong

A head-to-head comparison of the Drug Vote '08

The M&A Numbers

Sep 1, 2008
By: Walter Armstrong

Young & Partners crunches pharma's filings for, the first half of '08. The results? Ask the Japanese

RNA Revolutionaries

Could gene silencing be the next great innovation in drug development? Led by Alnylam, Isis, and Regulus, a bold bunch of biotechs are betting on it
Jul 1, 2008
By: Walter Armstrong

Could gene silencing be the next great innovation in drug development? Some biotechs are betting on it.

That Thing about RNA

No, it's not as glamorous as its double-helixed offspring. But recent revelations about RNA turn even cold-eyed scientists into lyrical romantics
Jul 1, 2008
By: Walter Armstrong

No, it's not as glamorous as its double-helixed offspring. But recent revelations about RNA turn even cold-eyed scientists into lyrical romantics